Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in...
49 insider purchases on record · latest filing 2026-09-17.
Insiders have also filed 1 sale transaction at TENX.